Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations by Fan, ST et al.
Title Clinical outcome and virologic profiles of severe hepatitis Bexacerbation due to YMDD mutations
Author(s) Yuen, MF; Kato, T; Mizokami, M; Chan, AOO; Yuen, JCH; Yuan,HJ; Wong, DKH; Sum, SM; Ng, IOL; Fan, ST; Lai, CL
Citation Journal Of Hepatology, 2003, v. 39 n. 5, p. 850-855
Issued Date 2003
URL http://hdl.handle.net/10722/77168
Rights Creative Commons: Attribution 3.0 Hong Kong License
                        Yuen et al.,P.1      
Clinical Outcome and Virologic Profiles of Severe Hepatitis B Exacerbation 
Due to YMDD Mutations 
Man-Fung Yuen1, Takanobu Kato2, Masashi Mizokami2, Annie On-On Chan1,    
John Chi-Hang Yuen1, He-Jun Yuan1, Danny Ka-Ho Wong1, Siu-Man Sum1,     
Irene Oi-Lin Ng3, Sheung-Tat Fan4, Ching-Lung Lai1
1Department of Medicine, 3Department of Pathology, 4 Department of Surgery, The 
University of Hong Kong, Queen Mary Hospital, Hong Kong 
2Department of Clinical Molecular Informative Medicine, Nagoya City University 
Graduate School of Medical Sciences, Kawasumi, Mizuho, Nagoya 467-8601, 
Japan. 
Short title: Severe Hepatitis B Exacerbation due to YMDD Mutants 
Reprints address and Correspondence: Prof. Ching-Lung Lai  
Department of Medicine, The University of Hong Kong,  
Queen Mary Hospital, Pokfulam Road, Hong Kong, China.  
Tel: (852) 28554252 Fax: (852) 28162863 
E-mail: hrmelcl@hkucc.hku.hk  
Keywords: severe hepatitis B exacerbation, YMDD mutation, hepatitic 
decompensation, mortality  
                        Yuen et al.,P.2      
Abstract 
Aim: To study the outcome and the virologic profiles of severe hepatitis 
exacerbations due to YMDD mutants in lamivudine-treated patients. 
Patients and Methods: Eighteen lamivudine-treated patients with severe hepatitis 
exacerbations due to YMDD mutants were recruited. Laboratory and clinical 
parameters were monitored. Viral genotypes and YMDD mutations were 
determined.  
Results: None of the 18 patients had YMDD wild-type during exacerbations.  
Three (16.7%) and 15 (83.3%) patients had genotypes B and C respectively. 
Elevated bilirubin levels and prolonged prothrombin time were found in 11 (61.1%) 
and 6 patients (33.3%) respectively. Three patients (16.7%) had adverse outcome 
with the development of ascites and/ or encephalopathy. One of these patients 
required liver transplantation and one died. Both patients had evidence of cirrhosis 
before treatment and HBeAg seroreversion from anti-HBe positivity. The remaining 
16 patients (88.9%) have no evidence of pre-existing cirrhosis. 37.5% patients had 
normal alanine aminotransferase levels at the last follow-up. The median HBV DNA 
level at the last follow-up was significantly lower than the pre-treatment level 
(p=0.009).  
Conclusions: Though the majority of patients with severe hepatitis exacerbations 
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due to YMDD mutants had uneventful course, early liver transplantation should be 
considered in patients with pre-existing cirrhosis and HBeAg seroreversion. 
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Background 
Lamivudine is one of the first line agents for the treatment of chronic hepatitis 
B (CHB) infection. The profound suppressive effect on hepatitis B virus (HBV) 
replication in both Asian and Caucasian patients, and the near absence of side effects 
are the two main reasons for its widespread use [1, 2]. The prolonged use of 
lamivudine, however, is associated with the development of drug resistant HBV 
virus mutations at the viral polymerase gene, namely YMDD mutations 
(tyrosine-methionine-aspartate-aspartate) changing to either YIDD (isoleucine) or 
YVDD (valine). The frequency of YMDD mutations increases with the duration of 
lamivudine treatment (15%, 38%, 56% and 67% for the first four years respectively) 
[2-5]. It has been shown both in in vitro and in vivo studies that compared with 
YMDD wild-type, YMDD mutants have less replication competence and are 
associated with less aggressive liver disease [6-11]. Nevertheless, severe hepatitis 
exacerbations due to YMDD mutants have been reported. These exacerbations are 
sometimes associated with hepatic decompensation and mortality [12-14]. To date, 
data on the mortality rate of severe hepatitis exacerbations due to YMDD mutants 
and the factors associated with mortality are unknown.  
The aims of the present study were to study the outcome and the virologic 
profiles of severe hepatitis exacerbations due to YMDD mutants in 
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lamivudine-treated patients. 
 
Patients and Methods 
From January 1999 to December 2002, all patients on lamivudine having 
severe HBV exacerbations admitted to Queen Mary Hospital, The University of 
Hong Kong, Hong Kong were prospectively assessed for the present study. Severe 
hepatitis exacerbation was defined as an increase in alanine aminotransferase (ALT) 
levels > 10 X upper limit of normal (ULN) after excluding other causes of ALT 
elevation including other viral hepatitis (A, C, D, E), drug-induced hepatitis, and 
alcoholic hepatitis. Eighteen patients fulfilled these criteria; all had YMDD 
mutations. Of these 18 patients, 8 patients who were on lamivudine from our 
previous clinical trials [1, 15] had regular follow-up in our Hepatitis Clinic, Queen 
Mary Hospital, The University of Hong Kong, Hong Kong, both before and 
throughout the course of lamivudine treatment. Pretreatment liver biopsies were 
performed in these 8 patients under trial protocols. They developed YMDD mutants 
at a median time of 8.5 (range 6.2 – 23.2) months after lamivudine therapy. The 
remaining 10 patients were referred to our hospital for further management when 
they developed the severe exacerbations. The intervals between the initiation of 
lamivudine therapy and the emergence of YMDD mutants for these 10 patients were 
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unknown. All 18 patients were maintained on lamivudine treatment till the time of 
writing. The complete blood count, liver biochemistry, HBV DNA levels, hepatitis B 
e antigen (HBeAg)/ antibody to HBeAg (anti-HBe) status before lamivudine 
treatment were recorded. 
Patients having severe exacerbations were closely monitored by checking the 
complete blood count, prothrombin time and liver biochemistry every 2 days till 
discharge or death. The HBV DNA levels were measured by Digene Hybrid Capture 
II assay (Digene Corporation, Gaithersburg, MD) (lower limit of detection 0.14 X 
106 copies/ml). The development of clinical complications including ascites, 
encephalopathy and variceal bleeding, was noted. “Adverse outcome” is defined as 
exacerbations resulting in development of the clinical complications mentioned 
above and/ or necessity of liver transplantation and/ or death. Patients recovering 
from the hepatic decompensation were regularly followed up every 4 weeks for the 
first 12 weeks and subsequently at 12 weekly intervals. The liver biochemistry, 
HBeAg/ anti-HBe status and HBV DNA levels were measured during every 
follow-up.   
A line probe assay (INNO-LiPA HBV DR, Innogenetics NV, Belgium) was used 
to determine the YMDD mutations. The methodology was described in our previous 
study [16]. The assay can detect mixed populations of YMDD wild-type and YMDD 
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mutations when the proportion of either viral strain is higher than 5% of the total 
population.  
The HBV genotypes were determined by enzyme-linked immunosorbent assay 
(ELISA) with type specific antibody and subtypes of Ba and Bj in genotype B were 
assayed by polymerase chain reaction – restriction fragment length polymorphism 
(PCR-RFLP) as described previously [17, 18]. 
The core promoter and precore mutations were determined in patients who 
were anti-HBe positive by direct sequencing. Briefly, serum HBV DNA, in a final 
volume of 200ul, was extracted from 200 μl of serum, using the QIAGEN DNA 
blood minikit (QIAGEN GmbH, Germany).  The HBV genome at nucleotide 
1653 – 1974 containing precore and core promoter regions was amplified by PCR 
using the primers HBV1 (5’-cataagaggactcttggact-3’) and HBV2 
(5’-ggaaagaagtcagaggc- 3’) in a GeneAmp 9700 PCR system (Applied Biosystems, 
US) with the following conditions: 950C for 10 mins, followed by 940C for 30s, 
540C for 30s and 720C for 1 min up to 40 cycles and a final extension 720C for 10 
mins. The 322 bp PCR products were purified by ethanol precipitation with 
ammonium acetate in a final volume of 20 μl.  Two microliter of the purified PCR 
products was used in a thermocycle sequencing with the DYEnamic ET Terminator 
Cycle Sequencing Kit as directed (Amersham Biosciences, Uppsala, Sweden) using 
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HBV2 as the primer.  Automated sequencing was performed with an ABI prism 
3700 DNA Analyzer. 
 
Statistical analysis 
The difference in the paired HBV DNA levels at the baseline and at the last 
follow-up was tested by Wilcoxon signed ranks test. The difference in the ALT 
levels before lamivudine treatment, during lamivudine treatment and at the last 
follow-up was tested by Kruskal Wallis test. P value of less than 0.05 is considered 
to be statistically significant. 
 
Results 
Clinical outcome of severe exacerbations 
The demographic data, liver biochemistry, HBV DNA, HBeAg/ anti-HBe status, 
strains of YMDD mutants, and the outcome of the severe hepatitis exacerbations are 
listed in Table 1.  
Elevated bilirubin levels and prolonged prothrombin time were found in 11 
(61.1%) and 6 patients (33.3%) respectively (Table 1). Eight patients (44.4%) and 
six patients (33.3%) had bilirubin levels elevated to more than 2 X ULN and 
prothrombin time prolonged by more than 3 seconds respectively. Three patients 
(16.7%) had adverse outcome with the development of ascites; one of these three 
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patients also developed encephalopathy. None had variceal bleeding.  
Two patients (11.1%) had irreversible hepatic decompensation. Adefovir 
dipivoxil was given 4 weeks after the severe hepatitis exacerbation in one patient in 
whom spontaneous recovery was unlikely to occur. However, because of the 
irreversible hepatic decompensation, liver transplantation was finally performed. 
The histology of the explanted liver showed that the liver was cirrhotic with 
regeneration nodules and fibrous septa. There was also submassive necrosis of the 
liver with loss of hepatocytes. Another patient died of hepatic decompensation 3 
weeks after admission, while compassionate use of adefovir dipivoxil and liver 
transplantation were being arranged. These two patients were the oldest (age 47 and 
51 years) of the 18 patients (Table 1). The HBV DNA levels of these two patients 
were not especially high. However, both patients had ultrasonographic evidence of 
small cirrhotic liver, splenomegaly and ascites before the start of lamivudine. They 
also had biochemical evidence of cirrhosis before treatment with low albumin levels, 
high bilirubin levels and low platelet count (Table 1). In contrast, the pretreatment 
histology of the 8 patients with pretreatment biopsies and who had uneventful course 
showed only mild to moderate inflammation without evidence of fibrosis or 
cirrhosis. Another feature was that both patients were anti-HBe positive before the 
severe exacerbation and had HBeAg seroreversion during the severe exacerbations. 
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These were the only two patients with HBeAg seroreversion. For the other 16 
patients, 15 were HBeAg positive and one was anti-HBe positive at the time of 
severe exacerbations. 
 
ALT levels and HBV DNA levels before, during and after severe exacerbations 
   The median duration of follow-up from the time of severe exacerbation to the 
last follow-up for the 16 patients with uneventful course was 19.2 (range 1.3 – 53.9) 
months. Thirteen patients remained HBeAg positive, 2 patients had HBeAg 
seroconversion to anti-HBe (at months 33 and 42 months after the severe 
exacerbations) and 1 patient was anti-HBe positive all along. Six out of these 16 
patients (37.5%) had normal ALT levels at the last follow-up. Among the 13 patients 
with the ALT results available before lamivudine treatment, during lamivudine 
treatment and at the last follow-up, there was no difference in the median ALT levels 
between these time points [61 (range 27 – 1189) vs. 47 (range 30 – 70) vs. 59 (range 
17 – 227) respectively, p=0.37]. Six patients (37.5%) had relatively low HBV DNA 
levels that were below the detection limit of the Digene Hybrid Capture II assay 
(<0.14 X 106 copies/ml) at the last follow-up. Among the 15 patients whose HBV 
DNA levels both before lamivudine treatment and at the last follow-up were 
available, the median HBV DNA level at the last follow-up was significantly lower 
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than at baseline [1.7 X 106 (range <0.142 – 806.3 X 106) vs. 263.8 X 106 (range 
<0.142 – 11,000 X 106) respectively, p=0.009]. 
 
Virologic profiles in severe exacerbations 
Three patients (16.7%) had HBV genotype B (all with Ba subtype) and 15 
patients (83.3%) had HBV genotype C.   
None of the 18 patients had detectable YMDD wild-type during the severe 
exacerbations indicating that the YMDD mutants [either single (YIDD or YVDD) 
(n=15) or mixed (YIDD & YVDD)(n=3)] became the predominant viral strains at 
the time of exacerbations. The changes in the viral populations of the 16 patients 
with uneventful course 3 months after the severe hepatitis exacerbations were also 
determined. There were no changes in the viral populations in 11 patients (68.8%) (4 
with YIDD alone, 5 with YVDD alone and 2 with YIDD & YVDD). Two patients 
(12.5%) (1 with YVDD alone, 1 with YIDD & YVDD) had the reappearance of 
YMDD wild-type in the presence of YMDD mutants. Two patients (12.5%) with 
YVDD mutants during the severe exacerbations had the addition of the YIDD 
mutants. The remaining patient (6.3%) changed the viral population from YIDD 
alone to YVDD alone. 
Among the 18 patients, 16 were HBeAg and 2 were anti-HBe positive when 
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lamivudine was started. One patient had HBeAg seroconversion before the severe 
exacerbation. In total, 15 patients were HBeAg positive and 3 patients were 
anti-HBe positive at the time of severe exacerbations. Among the 3 anti-HBe 
positive patients, 2 patients had serum 1, 3 and 6 months and 1 patient had serum 1 
month before the severe hepatitis exacerbations that were available for the 
determination of core promoter and precore mutations. The first 2 patients had the 
same core promoter mutations (A1762T & G1764A) and precore wild-type at the 
three time points. The last patient also had the same core promoter mutations and 
precore wild-type detected one month before the exacerbation. YMDD mutations 
were also determined in the 2 patients (one with and one without HBeAg 
seroreversion) with available serum at 1, 3 and 6 months prior the severe hepatitis 
exacerbations. For the patient with HBeAg seroreversion, the YMDD mutant (YIDD) 
was already present 6 months before the severe exacerbation. The patient without 
HBeAg seroreversion had YMDD wild-type at 3 and 6 months before the 
exacerbation; YMDD mutation (YVDD) was only present 1 month before the severe 
exacerbation.  
 
Discussion 
The results of this study provide essential information on the clinical outcome 
                        Yuen et al.,P.13      
and virologic profiles of patients with severe exacerbations due to YMDD mutations. 
These findings are important for patient management.  
According to Liaw and his colleagues, in a study of 55 patients, acute 
exacerbations occur in 41% of patients with YMDD mutants at a median interval of 
24 weeks after the emergence of the YMDD mutants [12]. In these patients, 9.4% 
develop hepatic decompensation.  The present study examined only patients with 
severe exacerbations (ALT > 10 X ULN). Significant prolongation of prothrombin 
time was observed in 33.3% patients and adverse outcome with the development of 
ascites and/or encephalopathy occurred in three patients (16.7%). Of these, two 
patients had irreversible hepatic decompensation (11.1%) (one required liver 
transplantation, one died). These findings suggest that severe exacerbations due to 
YMDD mutants can cause considerable morbidity and mortality though the majority 
of patients run an uneventful course.  
The HBV DNA levels in the two patients with irreversible hepatic 
decompensation were not especially high (Table 1) indicating the viral load by the 
time of presentation was not an important prognostic factor. However there were 
two features that were special for both patients. Both patients had ultrasonographic 
(small sized liver, splenomegaly and ascites), biochemical/hematological (albumin 
levels of 32 and 33 g/L, bilirubin levels of 25 μmol/L and platelet count of 56 and 99 
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X 106/ L) and histologic (in one patient) evidence of pre-existing cirrhosis. Malik 
and Lee also describe two deaths occurring in a small number of patients with 
advanced HBV disease on lamivudine therapy [19]. In contrast, the eight patients of 
the present study with pretreatment liver biopsy and with uneventful course did not 
have evidence of fibrosis or cirrhosis. In all the 16 patients without irreversible 
hepatic decompensation, the pretreatment albumin levels were normal or near 
normal (range 39 – 49 g/L) (Table 1).  
Another relevant point is that both these patients with irreversible hepatic 
decompensation had HBeAg seroreversion during the severe exacerbations. This has 
two implications. Firstly, the seroreversion probably signified a very severe 
immunologic reaction. Secondly, in a proportion of Asian chronic hepatitis B 
patients, the process of HBeAg seroconversion and the accompanying 
immune-related damage may worsen the liver function [20, 21]. This may set the 
stage for more severe outcome during a subsequent acute exacerbation. Early 
transplantation with adefovir dipivoxil cover should be considered for patients with 
pre-existing cirrhosis and HBeAg seroreversion during the severe exacerbations due 
to YMDD mutations.  
For the 16 patients with uneventful course, 37.5% had normal ALT levels and 
37.5% had HBV DNA levels < 0.14 X 106 copies/ml at the last follow-up (Table 1). 
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Among the 15 patients who had available HBV DNA levels both before lamivudine 
treatment and at the last follow-up, the median HBV DNA level at the last follow-up 
was significantly lower than that pre-treatment level (p=0.009). It indicated that the 
majority of patients who recovered from the severe exacerbations still have a much 
lower viral activity than that at the baseline. Nevertheless, at least 62.5% patients 
still had elevated ALT levels and HBV DNA levels > 105 copies/ml. Treating this 
subgroup of patients with adefovir dipivoxil or other newer nucleoside analogues 
that are effective against YMDD mutants may be of benefits.  
Akuta and his colleagues show that there is no difference in the chance of 
emergence of YMDD mutations between patients with genotypes B and C [22]. This 
has been confirmed in another study from our center [23]. In the present study, of 
the 18 patients with severe exacerbations due to YMDD mutants, 16.7% and 83.3% 
were genotypes Ba and C respectively. In our locality, the percentages of HBV 
patients with genotypes B and C are around 28% and 61% respectively [24]. Thus, 
genotypes also do not appear to play any role in predisposing patients to severe 
exacerbations due to YMDD mutants, though a large study is required to confirm 
this.  
In all the 18 patients at the time of the exacerbations, the YMDD wild-type 
virus was not detected by the LiPA which is capable of detecting mixed populations 
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of YMDD mutants and wild-type if either viral strain contributes more than 5% in 
the population [16]. This phenomenon suggests that severe exacerbations during 
lamivudine therapy are unlikely to be due to YMDD wild-type. According to Zhou 
et al., the viral load in the body increases gradually while YMDD mutants are 
gradually replacing YMDD wild-type in the viral population [25]. In our previous 
study, patients with YMDD mutants in the absence of YMDD wild-type are more 
likely to have HBV DNA breakthroughs [16]. In the present study, we further 
documented that the viral population remained unchanged 3 months after the severe 
exacerbations in 68.8% of the patients. In addition, 2 patients had the reappearance 
of YMDD wild-type 3 months after the severe exacerbations. The replacement of the 
YMDD mutants and emergence of different viral strains after exacerbation have 
been reported in several studies. Liaw and his colleagues show that clearance of 
YMDD mutants can occur after severe exacerbations [12]. Yeh and his colleagues 
also show that new distinct mutants may arise during prolonged lamivudine therapy 
[26]. In addition, mutations of the ‘a’ determinant of the viral envelope gene together 
with YMDD mutations in liver transplant recipients receiving lamivudine and 
hepatitis B immune globulin have been described by Bock and his colleagues [27]. 
Further longitudinal studies are required to examine the clinical importance of all 
these possible virologic changes after severe exacerbations due to YMDD mutants. 
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In conclusion, the present cohort study suggested that majority (88.9%) of 
patients with severe hepatitis exacerbation due to YMDD mutants had uneventful 
course. Early use of adefovir dipivoxil and/ or liver transplantation should be 
considered in patients with pre-existing cirrhosis and HBeAg seroreversion during 
the exacerbations because these patients had a higher chance of irreversible hepatic 
decompensation. 
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9 2 31 49 11 147 155 11000 + 28.1 V 40 22 1136 140 10.9 0.18 + 20.7 42 22 11 11.4 56.9 
10 1 35 45 11 61 238 74.8 + 41.1 I/V 41 24 976 164 11.3 1900 + 27 44 32 20 <0.14 95 
11 1 35 na na na na Na + 12.0 V 48 15 1980 212 12.4 4 + # 48 79 15 29.2 14.3 
12 1 37 45 11 39 273 134.9 + 90.7 V 39 17 575 263 12 594 + # 41 145 21 806.3 95.3 
13 1 41 47 7 41 177 263.8 + 35.9 V 41 9 990 157 11.6 304.7 + 30.2 44 17 10 <0.14 86.6 
14 1 42 45 22 1189 175 <0.14 + 20.7 I 39 42 900 56 15.7 936 + # 44 227 28 155.5 30.2 
15 1 46 39 14 78 76 330 - 27.8 V 40 13 1067 66 10.8 1.44 - # 43 83 13 33.8 31.5 
16 1 46 44 17 634 na 100 + 16.8 V 46 293 3910 73 18.8 106 + 2.3 44 52 22 11.4 19.1 
17*,§ 1 47 33 25 30 99 0.22 - 7.8 I 33 602 1000 87 37.5 1639 + x x x x x 16.5 
18†,§ 1 51 32 25 35 56 498 + 39 I 38 870 1199 72 45.7 24 + x x x x x 39.9 
Bold values indicate bilirubin levels elevated to > 2 X upper limit of normal (normal < 19 μmol/L) and prothrombin time greater than 3 seconds of controls  
Units: Albumin (g/L); Bilirubin (μmol/L); ALT (U/L); Platelet (X 109/L); HBV DNA (X 106 copies/ml); PT (seconds); Duration of follow-up (months) 
+: positive; -: negative; na: not available; lam: lamivudine; PT: prothrombin time; I: YIDD; V: YVDD; Sex: 1=Male, 2=Female; FU: follow-up 
*Patient with liver transplantation, † Patient who died, § Patients with HBeAg seroreversion, x not applicable 
Table 1: Clinical details of the 18 patients with severe hepatic exacerbations due to YMDD mutations 
                       Yuen et al.,P.23      
# duration of hepatic exacerbation not applicable because of persistent elevated ALT levels 
 
